Browsing by Author "Makharadze, T."
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Item Cemiplimab for Advanced Non-Small Cell Lung Cancer: Squamous Subgroup Analysis for EMPOWER-Lung 1 And 3(2023) Makharadze, T.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Penkov, K. D.; Giorgadze, D.; Ozguroglu, M.; Kalinka, E.; McIntyre, D.; Kaul, M.; Quek, R. G. W.; Pouliot, J-F.; Seebach, F.; Gullo, G.; Rietschel, P.Item Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3(2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.; Li, Y.; Li, S.; Salvati, M.; Pouliot, J. -F.; Seebach, F.; Lowy, I.; Gullo, G.; Rietschel, P.Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item Predictive Utility of Patient Reported Outcomes for Survival in 1st-Line Treated Patients with a NSCLC in EMPOWER-Lung 1 and 3(2023) Gandara, D. R.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Guemues, M.; McIntyre, D. A.; He, X.; Yan, E.; Gullo, G.; Rietschel, P.; Quek, R. G.